Clinical Trials Related to Borderline Resectable Pancreatic Cancer

Related studies linked through entity extraction aliases.

PDAC Regression and Intraoperative Surgical Margin With Neoadjuvant TAMP (PRISM-TAMP)

Status: NOT_YET_RECRUITING
Phase: PHASE1/PHASE2

EUS-guided CTCs + Multi-omics: Predicting Pancreatic Cancer Recurrence and Metastases

Status: NOT_YET_RECRUITING
Phase: N/A

Chemotherapy With or Without IMD10 (Focused Ultrasound) in the Treatment of Borderline Resectable or Locally Advanced Pancreatic Cancer

Status: NOT_YET_RECRUITING
Phase: NA

A New Clinical Pathway for Personalized Management of Borderline Resectable and Locally Advanced Pancreatic Cancer

Status: RECRUITING
Phase: N/A

Irinotecan Liposome II in Combination With 5-FU/LV and Oxaliplatin in Perioperative Treatment of Borderline Resectable Pancreatic Cancer

Status: RECRUITING
Phase: PHASE2

NALIRIFOX in Combination With Camrelizumab for BRPC: a Prospective, Exploratory Study

Status: RECRUITING
Phase: PHASE2

Laparoscopic Versus Open Pancreatoduodenectomy Following Neoadjuvant Chemotherapy for BRPC

Status: RECRUITING
Phase: NA

Phase 2b Study of GC4711 in Combination With SBRT for Nonmetastatic Pancreatic Cancer

Status: TERMINATED
Phase: PHASE2

AG vs mFOLFIRINOX as Neoadjuvant Therapy for Borderline Reseactable and Locally Advanced Pancreatic Cancer

Status: UNKNOWN
Phase: PHASE3

IORT on Borderline Resectable Pancreatic Cancer

Status: SUSPENDED
Phase: PHASE2

Neoadjuvant Nab-Paclitaxel and S-1 in Borderline Resectable Pancreatic Cancer

Status: UNKNOWN
Phase: PHASE2

Divestment for Artery-involved Pancreatic Cancer

Status: UNKNOWN
Phase: NA

Neoadjuvant FOLFIRINOX or Nab-paclitaxel With Gemcitabine for Borderline Resectable Pancreatic Cancer

Status: UNKNOWN
Phase: PHASE2

Phase II Neoadjuvant Chemotheraphy (Gemcitabine and Nab-Paclitaxel vs. mFOLFIRINOX) and Sterotatic Body Radiation Therapy for Borderline Resectable Pancreatic Cancer

Status: TERMINATED
Phase: PHASE2